Welcome to our dedicated page for KESTRA MED TECHNOLOGIES news (Ticker: KMTS), a resource for investors and traders seeking the latest updates and insights on KESTRA MED TECHNOLOGIES stock.
News for Kestra Medical Technologies, Ltd. (Nasdaq: KMTS) focuses on its activities as a commercial-stage wearable medical device and digital healthcare company in cardiovascular care. Company announcements highlight developments related to its Cardiac Recovery System platform and ASSURE Wearable Cardioverter Defibrillator (ASSURE WCD), as well as financial performance and capital markets activity.
Investors and clinicians following KMTS news will see updates on clinical evidence, including communications about the ASSURE WCD Clinical Evaluation Post-Approval Study (ACE-PAS), which Kestra describes as the largest prospective real-world study of wearable defibrillators to date. Press releases detail study design and key endpoints such as shock conversion success, inappropriate shock rates, wear time, and detection of additional arrhythmias in diverse cardiac recovery populations.
Kestra’s news flow also includes information on strategic collaborations, such as its agreement with Biobeat Technologies, Ltd. to integrate FDA-cleared, cuffless ambulatory blood pressure monitoring into the ASSURE WCD ecosystem. These items explain how additional diagnostic data, like 24-hour blood pressure measurements, may expand the clinical insights available for patients prescribed the wearable defibrillator.
Financial and corporate updates are another key component of KMTS coverage. The company issues press releases on quarterly financial results, preliminary revenue and margin trends, and public offerings of common shares. It also announces participation in major healthcare and investor conferences, including cardiology meetings and investment bank conferences, where management presents Kestra’s strategy and platform.
This news page aggregates these disclosures so readers can track Kestra’s clinical milestones, technology integrations, financial updates, and conference appearances in one place. For ongoing research into KMTS, users can review both operational announcements and regulatory communications as they are released.
Kestra Medical Technologies (NASDAQ:KMTS), a wearable medical device company, reported strong Q4 and FY2025 results. Q4 revenue reached $17.2 million, up 71% year-over-year, while FY25 revenue hit $59.8 million, a 115% increase from FY24. The company's ASSURE® cardiac recovery system saw 13,193 prescriptions in FY25, up 72% from the previous year.
Gross margins significantly improved to 44.3% in Q4 FY25 from 13.9% in the prior year, and 40.5% for FY25 compared to 1.3% in FY24. Despite growth, the company reported a GAAP net loss of $51.1 million in Q4 and $113.8 million for FY25. Looking ahead, Kestra projects FY26 revenue of $85 million, representing 42% growth.
[ "Revenue grew 115% year-over-year to $59.8 million in FY25", "Significant gross margin expansion to 40.5% in FY25 from 1.3% in FY24", "Strong prescription growth with 13,193 ASSURE® system prescriptions in FY25, up 72%", "Robust cash position of $237.6 million as of April 30, 2025", "Projected 42% revenue growth for FY26 with $85 million guidance" ]Kestra Medical Technologies (Nasdaq: KMTS), a wearable medical device and digital healthcare company, has scheduled its fourth quarter and fiscal year 2025 financial results announcement for Tuesday, July 15, 2025. The company will host a conference call at 4:30 p.m. Eastern Time to discuss the results. Investors can access both the live and archived webcast through the "Events" section of Kestra's investor relations website, with registration recommended at least 10 minutes before the call.
Kestra Medical Technologies (Nasdaq: KMTS), a company specializing in wearable medical devices and digital healthcare, has announced its participation in two major upcoming investor conferences.
The company will present at the following events:
- BofA Securities 2025 Health Care Conference on May 14 at 6:40 p.m. ET
- Goldman Sachs 46th Annual Global Healthcare Conference 2025 on June 11 at 8:00 a.m. ET
Investors and interested parties can access live webcasts and replays of both presentations through Kestra Medical Technologies' investor relations website.
Kestra Medical Technologies presented new real-world data for their ASSURE Wearable Cardioverter Defibrillator (WCD) at Heart Rhythm 2025 in San Diego. The study focused on outcomes in a community-based setting using an advanced practice provider (APP)-driven protocol.
Key findings demonstrate:
- High patient compliance with 23.3 hours median daily wear time
- Consistent usage beyond 90 days
- 4% of patients showed ventricular arrhythmias detection
- Successful implementation of APP-driven care model
- Effective continuity of care through ICD placement or hospitalization when needed
The study validates ASSURE's effectiveness in protecting patients from sudden cardiac arrest through both clinical performance and patient engagement. The results highlight the success of structured, team-based approaches in expanding access to cardiac care within community settings.
Kestra Medical Technologies (Nasdaq: KMTS) announced its participation in Heart Rhythm 2025, the annual Heart Rhythm Society meeting, scheduled for April 24-27 at the San Diego Convention Center. This marks the company's first major industry showcase following its recent IPO.
The company will showcase its ASSURE® system, a wearable medical device that combines defibrillation therapy with diagnostic and patient support capabilities. The exhibition will feature an immersive in-booth experience demonstrating the system's role in protecting patients at risk of sudden cardiac arrest.
During the event, Kestra will present new real-world clinical data about the ASSURE system's impact and continue its sponsorship of the Women in EP Luncheon for the fourth consecutive year.
Kestra Medical Technologies (NASDAQ: KMTS) reported strong Q3 FY25 financial results with revenue of $15.1 million, up 82% year-over-year. The company achieved a significant improvement in gross margin to 43.4% from 10.6% in the prior year period.
Key highlights include 3,459 prescriptions written for the ASSURE® system, representing a 51% increase. The company successfully completed its IPO in March 2025, raising $205.2 million in net proceeds. Kestra expanded its insurance coverage network, now reaching over 285 million health plan members in the United States.
For fiscal year 2025 ending April 30, Kestra projects revenue between $58.0-58.5 million, indicating approximately 109-110% growth compared to FY24. However, the company reported a GAAP net loss of $21.8 million and an adjusted EBITDA loss of $16.3 million for Q3 FY25.
Nalu Medical has appointed Raymond W. Cohen as chairman of its board of directors. Cohen previously served as CEO and board member of Axonics, a medical device company he co-founded in 2013 and took public in 2018. Under his leadership, Axonics achieved recognition as the fastest-growing company in the Americas by Deloitte and Financial Times in 2021 and 2022.
Cohen recently oversaw Axonics' $3.7 billion sale to Boston Scientific (NYSE: BSX) in November 2024. He also served as chairman of SoniVie, which was sold to BSX for $600 million in March 2025. Currently, he serves on the board of Kestra Medical Technologies (Nasdaq: KMTS), which recently completed a $232 million IPO.